Ousia, there is a great deal of data around that suggests your "realised" prices are about 20/25% over expectations, including the last Q report that suggested Chinese domestic "plus".
A quarter's lost production is still a quarter of lost sales revenue, and probably more importantly a lost opportunity to lock contract customers in.
You're missing the reality of customer qualification in that it differs from a few weeks to several months depending on element & customer. Lynas is unable to supply those that have accepted or those that will in the next month or so, and if any want material with varied spec for further qualification Lynas is unable to produce that either.
I've already made my point re competition with Moly in Japan, not good, particularly as Ph2 is underpinned by Japanese sales.
Risk has now skewed away from market, which does appear to be improving, back to execution, and a black hole for 11 weeks.
- Forums
- ASX - By Stock
- LYC
- lyc risk reward equation
LYC
lynas rare earths limited
Add to My Watchlist
0.84%
!
$8.27

lyc risk reward equation, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$8.27 |
Change
-0.070(0.84%) |
Mkt cap ! $7.736B |
Open | High | Low | Value | Volume |
$8.30 | $8.35 | $8.14 | $30.78M | 3.743M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 184 | $8.27 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$8.28 | 38197 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 70 | 8.270 |
1 | 3175 | 8.220 |
1 | 1000 | 8.200 |
2 | 4000 | 8.190 |
2 | 1307 | 8.140 |
Price($) | Vol. | No. |
---|---|---|
8.300 | 3800 | 2 |
8.320 | 6490 | 2 |
8.340 | 7002 | 1 |
8.380 | 1000 | 1 |
8.400 | 755 | 2 |
Last trade - 16.15pm 04/07/2025 (20 minute delay) ? |
Featured News
LYC (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online